Article
Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2015
Ayeni Deborah, Politi Katerina, Goldberg Sarah B
Abstract excerpt
Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.